{"filing":{"accession_number":"0001193125-26-429509","cik":"0001774857","ticker":"AARD","company_name":"Aardvark Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"ck0001774857-20261023.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526429509/ck0001774857-20261023.htm"},"events":[{"id":37459,"run_id":34528,"accession_number":"0001193125-26-429509","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Aardvark disclosed exploratory efficacy and safety data from its terminated Phase 3 HERO trial and open-label extension trial for ARD-101, along with the FDA's lifting of the clinical hold and plans to resume clinical activities in 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company—the data disclosure, regulatory clearance, and path-forward announcement would affect a reasonable investor's assessment of the drug development program's viability. While the data are explicitly labeled \"exploratory\" due to early termination, the convergence of efficacy signals, safety profile, and regulatory progress constitute a significant operational development that does not fit neatly into the specific financial, governance, or legal categories.","company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42177,"accession_number":"0001193125-26-429509","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aardvark disclosed exploratory efficacy and safety data from its terminated Phase 3 HERO trial and open-label extension trial for ARD-101, along with the FDA's lifting of the clinical hold and plans to resume clinical activities in 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company—the data disclosure, regulatory clearance, and path-forward announcement would affect a reasonable investor's assessment of the drug development program's viability. While the data are explicitly labeled \"exploratory\" due to early termination, the convergence of efficacy signals, safety profile, and regulatory progress constitute a significant operational development that does not fit neatly into the specific financial, governance, or legal categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T12:45:56.240964+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42177,"accession_number":"0001193125-26-429509","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aardvark disclosed exploratory efficacy and safety data from its terminated Phase 3 HERO trial and open-label extension trial for ARD-101, along with the FDA's lifting of the clinical hold and plans to resume clinical activities in 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company—the data disclosure, regulatory clearance, and path-forward announcement would affect a reasonable investor's assessment of the drug development program's viability. While the data are explicitly labeled \"exploratory\" due to early termination, the convergence of efficacy signals, safety profile, and regulatory progress constitute a significant operational development that does not fit neatly into the specific financial, governance, or legal categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T12:45:56.240964+00:00","company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","filing_date":"2026-10-23"}]}